The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
In addition to the shortage of Concerta and Methylphenidate-Teva XR products, Ritalin and Artige immediate-release tablets are now also in shortage. A shortage of Ritalin LA capsules is anticipated, starting from 21 April 2025 for the 30 mg strength, and from May, June and July 2025 for the other strengths.
These medicines are used to treat attention deficit hyperactivity disorder (ADHD).
We acknowledge the concerns and difficulties caused by such shortages, especially due to the specific requirements for prescribing and dispensing methylphenidate hydrochloride. We hope this notification will give patients and prescribers the opportunity to plan ahead.
We urge patients who are affected by these shortages to speak with their pharmacist about their supply of medicine. We also suggest patients consult with their prescribers early about their treatment plan, as they may need a new prescription.
Another methylphenidate medicine remains available, and overseas-registered Concerta tablets can be supplied. Other medicines approved to treat ADHD are also available.
Please go to About the shortage of methylphenidate hydrochloride products for more information.
You can also go to the Medicine Shortage Reports Database (search for ‘methylphenidate’) for the most up-to-date information.